Bristol-Myers Empliciti Combo Fails In First-Line Myeloma Study
Zacks Investment Research | Mar 09, 2020 09:50PM ET
Bristol-Myers Squibb Company (NYSE:BMY) announced that a phase III ELOQUENT-1 study evaluating Empliciti (elotuzumab) triplet combination in first-line patients with multiple myeloma, who are transplant ineligible, failed to meet its primary endpoint.
The ELOQUENT-1 study compared Empliciti in combination with Revlimid plus dexamethasone (ERd) to a combination of Revlimid and dexamethasone (Rd) in newly diagnosed, previously untreated multiple myeloma patients, who are ineligible for a transplant, for improvement in progression-free survival ("PFS"). Data from the study showed that the ERd combo failed to demonstrate statistically significant improvement in PFS. However, safety profile of the Empliciti triplet combination was consistent with previous clinical studies.
Detailed data from the study will be presented at a future medical meeting.
Please note that ERd combo is already approved for the treatment of relapsed and refractory multiple myeloma (r/rMM) in second or later-line settings. The treatment regimen is also the standard of care in its approved indication. Empliciti is also approved in combination with Pomalyst plus dexamethasone for treating multiple myeloma patients, who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Bristol-Myers co-develops Empliciti in collaboration with AbbVie (NYSE:ABBV) . Bristol-Myers is solely responsible for the drug’s commercialization activities.
Shares of Bristol-Myers have increased 13.3% in the past year against the industry ’s decrease of 0.8%.
The drug generated sales of $257 million in 2019, up 44.5% year over year. A successful development as a treatment for first-line multiple myeloma may have further boosted the drug’s prospect. Bristol-Myers is currently evaluating the drug in combination with its blockbuster immuno-oncology drug, Opdivo, in a phase II study as a treatment for r/rMM.
Meanwhile, Bristol-Myers key drug, Opdivo continues to perform well, driven by label expansions. However, the drug faces stiff competition globally from Merck (NYSE:MRK) PD-1 inhibitor, Keytruda, and Roche’s (OTC:RHHBY) PD-L1 inhibitor,Tecentriq.
Bristol-Myers Squibb Company Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.